FDA updates drug testing rules to clarify non-animal options

The FDA has updated its regulations for human drugs and biologics to clarify that non-animal testing methods may be used when appropriate before a product enters human clinical trials. In a direct final rule published September 22, 2026, the agency revised longstanding regulatory language so sponsors are no longer pointed primarily to “animal tests” or “animal studies,” but to broader “nonclinical” testing concepts that can include validated non-animal approaches. (fda.gov)

The move is less a sudden policy reversal than the latest step in a longer regulatory shift. Congress passed the FDA Modernization Act 2.0 in December 2022, clarifying that drug developers could use non-animal alternatives in support of investigational new drug applications and certain biologics submissions. The Food and Drug Omnibus Reform Act of 2022 then added statutory definitions for “nonclinical test” and related terms. FDA’s new rule largely brings the agency’s regulations into line with those statutory changes and with the scientific reality that many preclinical questions can now be approached with tools beyond traditional animal models. (govinfo.gov)

In practical terms, FDA said the rule replaces terms such as “animal test” and “animal study” with “nonclinical test” and “nonclinical study,” and also makes related terminology updates for consistency across drug and biologics regulations. The agency said those broader terms are meant to encompass animal studies when needed, but also scientifically valid NAMs, including human cell-based assays, organoids, organs-on-chips, and in silico models. FDA simultaneously highlighted a new database intended to show real examples of how NAMs have been used in regulatory decision-making, positioning the rule as part of a broader effort to make those pathways more visible and usable for sponsors. (govinfo.gov)

This rule also follows several related FDA actions in 2026. In March, the agency released draft guidance on general considerations for using NAMs in drug development, laying out a validation framework for sponsors. In May, FDA issued draft guidance aimed at reducing unnecessary animal testing for certain oncology products. HHS has framed these actions collectively as part of a department-wide push toward human-based research methods that may improve human relevance while reducing animal use. (fda.gov)

Public commentary around the rule has largely been supportive, at least from the federal and policy side. FDA said the update reflects scientific and technological advances that have expanded the testing toolbox, while HHS described the action as giving developers greater ability to use scientifically validated alternatives to animal testing. The Federal Register notice is more measured, noting that the agency expects the rule to foster development and use of scientifically valid new testing methodologies, even if the benefits are not yet easy to quantify. That cautious framing matters: FDA is encouraging broader use of NAMs, but not declaring animal studies obsolete across the board. (fda.gov)

Why it matters: For veterinary professionals, the immediate regulatory impact is indirect because the rule applies to human drugs and biologics, not to veterinary products regulated through FDA’s Center for Veterinary Medicine. But the signal is important. It reinforces a One Health-adjacent trend toward more mechanistic, human-relevant, and potentially faster preclinical evidence generation. For veterinarians involved in research, laboratory animal medicine, toxicology, academic-industry collaboration, or comparative translational work, the shift could gradually change study design, sponsor expectations, and conversations around when animal models are necessary, and when other data may be enough. FDA’s own veterinary innovation agenda has already emphasized modernization and cross-center coordination, suggesting this human-drug policy shift may be watched closely across animal health. (fda.gov)

There are also practical downstream implications for industry. As sponsors gain more confidence that FDA will review NAM-based packages seriously, contract research organizations, platform developers, and translational researchers may see stronger demand for organ-on-chip systems, computational toxicology, advanced in vitro assays, and hybrid evidence packages. At the same time, the bar remains scientific validity. FDA’s guidance makes clear that NAMs must be fit for purpose, reliable, and adequately validated for the specific regulatory question at hand. (fda.gov)

What to watch: The direct final rule is open for comment through December 7, 2026, and FDA has said it will confirm the effective date within 30 days after the comment period closes unless significant adverse comments force a withdrawal. Beyond that, the bigger story is whether FDA turns this terminology update into routine regulatory practice through finalized guidance, more public case examples, and broader acceptance of NAM-based submissions. (public-inspection.federalregister.gov)